Estimates of medical care expenditures for cervical and other malignancies caused by the human papillomavirus (HPV) are greater in recent research than in previous studies. The goal of this paper is to (1) evaluate and summarise current cancer cost estimates, and (2) show how the projected cost-effectiveness of the HPV vaccine may alter when these cost estimates are applied. The review of the literature turned up six publications that offered updated medical care cost estimates for five HPV-related malignancies. Researchers discovered that using current cancer cost estimates had a significant influence on the estimated medical expenses avoided by HPV vaccination over a long time period, and a modest impact on the estimated cost per quality-adjusted life-year (QALY) gained by the HPV vaccine. For example, adding the most recent cancer costs to catch-up immunization of teens and young adults decreased the projected cost per QALY gained by roughly $12,400.
The cost studies found in the literature analysis are up to date and based on credible data sources from US settings, and they can help influence future research of HPV vaccination cost-effectiveness in the US. However, due diligence is required to establish the most acceptable cost values to apply.